LGND
Ligand Pharmaceuticals Incorporated
301.50$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 71.8% | 40.4% | 27.1% | 35.3% | 69.0% | 75.2% | 36.7% | 35.8% | 34.6% | 30.2% | 35.2% | 53.3% | |
| 64.9% | 37.5% | 23.4% | 30.1% | 57.0% | 4.8% | 3.5% | 1.5% | 5.9% | 2.9% | 7.7% | 11.2% | |
| 64.9% | 37.5% | 23.4% | 30.1% | 60.6% | 71.6% | 30.2% | 26.3% | 27.8% | 21.6% | 27.2% | 47.0% | |
| 5.3% | 2.2% | 3.0% | 4.4% | 4.4% | 2.8% | 4.3% | 7.1% | 4.6% | 5.0% | 4.5% | 3.9% | |
| 0.1% | 0.3% | 0.3% | 0.7% | 0.6% | 0.5% | 1.9% | 2.1% | 1.7% | 3.0% | 1.5% | 0.6% | |
| 0.3% | 0.1% | 0.3% | 0.6% | 0.4% | 0.5% | 1.1% | 2.5% | 3.6% | – | – | – | |
| 24.4% | 11.3% | 46.0% | 46.9% | 24.3% | 6.4% | 13.9% | 8.1% | 13.9% | 13.1% | 11.2% | 6.5% | |
| 1.8% | 1.6% | 4.3% | 2.9% | 2.5% | 15.4% | 44.5% | 29.8% | 46.2% | 38.1% | 28.3% | 27.1% | |
| 90.5% | 43.0% | 38.4% | 37.6% | 55.5% | 48.7% | 47.9% | 36.7% | 21.7% | 11.0% | 11.8% | 34.8% | |
| 8.8% | 3.9% | 37.8% | 35.6% | 6.5% | 1.1% | 7.3% | 3.2% | 13.0% | 2.1% | 3.9% | 2.4% | |
| 0.1% | 37.8% | 35.4% | 33.5% | 2.1% | 0.1% | 0.6% | 0.1% | 10.1% | 0.1% | 0.1% | 0.1% | |
| 3.0% | 0.8% | 1.5% | 1.4% | 0.3% | 0.2% | 0.3% | 0.6% | 0.7% | 0.3% | 0.6% | 0.2% | |
| 1.2% | 7.4% | 4.9% | 2.8% | 48.4% | 42.7% | 32.5% | 24.7% | – | – | – | 28.6% | |
| 10.2% | 57.0% | 61.6% | 62.4% | 44.5% | 51.3% | 52.1% | 63.3% | 78.3% | 89.0% | 88.2% | 65.2% | |
| -255.5% | -75.3% | -71.7% | -59.7% | -18.2% | 26.8% | 28.8% | 34.6% | 59.1% | 63.9% | 53.0% | 39.0% | |
| 8.3% | 4.0% | 3.5% | 3.5% | 1.9% | 1.3% | 1.2% | 1.3% | 2.2% | 2.3% | 1.9% | 1.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.